Regulatory News:
ASIT biotech (Paris:ASIT) (BSE:ASIT) (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces its preliminary financial calendar for 2017.
Event | Date * | ||
2016 Full-Year Results | Friday, April 21, 2017 | ||
Shareholders’ General Meeting | Thursday, June 8, 2017 | ||
2017 Half-Year Results | Friday, September 15, 2017 |
Financial year ended December 31
* Subject to modification. Press releases are distributed before the financial markets open.
***
About ASIT biotech
ASIT biotech is a Belgian clinical stage
biopharmaceutical company focused on the development and future
commercialisation of a range of breakthrough immunotherapy products for
the treatment of allergies. Thanks to its innovative ASIT+TM
technology platform, ASIT biotech is currently the only developer of AIT
product candidates consisting of a unique mixture of highly purified
natural allergen fragments in an optimal size selection. This innovation
results in a short treatment, expected to improve patient compliance and
real-life effectiveness. ASIT biotech’s product pipeline entails two
novel ASIT+™ product candidates targeting respiratory allergy with the
highest prevalence (i.e. grass pollen: gp-ASIT+TM and house
dust mite: hdm-ASIT+TM), that could significantly expand the
current immunotherapy market. The Company believes that its innovative
ASIT+™ platform is flexible and would be applicable across a range of
allergies.
ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.
Further information can be found at: www.asitbiotech.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170103005940/en/